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C ancer pain is one of the most common symptoms associated with cancer,  and palliation of cancer 
pain is thus an important issue in cancer care.  Several 
clinical guidelines for cancer pain management have 
been published [National Comprehensive Cancer 
Network: NCCN Clinical Practice Guidelines in 
Oncology,  Adult Cancer Pain.  http: //www.nccn.org/
professionals/physician_gls/PDF/pain.pdf (accessed 
November 2 2020)] [1-3],  with the World Health 
Organization (WHO) analgesic ladder being recog-
nized as the standard in cancer pain management [4].  
Treatment of cancer pain has been proposed to be feasi-
ble for 70-90% of cancer patients [5].  However,  despite 
the publication of pain management guidelines,  many 
cancer patients remain undertreated [6-9].  Indeed,  a 
large proportion of patients have considerable pain,  but 
receive inadequate analgesia [10].  Furthermore,  many 
cancer outpatients have been reported to receive inade-
quate pain relief and to have incorrect information 
about opioids [11].  Unrelieved pain denies comfort to 
the patients and significantly affects their activities,  
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This study aimed to evaluate whether there are differences in the attitudes and practices of cancer pain manage-
ment between medical oncologists and palliative care physicians.  An online nationwide survey was used to 
collect responses from board-certified medical oncologists and palliative care physicians in Japan.  The survey 
questionnaire comprised 30 questions.  The differences in responses between medical oncologists and palliative 
care physicians were examined.  Out of the 1,227 questionnaires sent,  522 (42.5%) were returned.  After apply-
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opioids due to fear of adverse effects as the greatest barrier.  Significantly different ratings between medical 
oncologists and palliative care physicians were observed on 5 of the 8 questions in this area.  Significantly differ-
ent ratings were observed for all questions concerning pain specialists and their knowledge.  For effective cancer 
pain management,  it is important to account for differences in attitudes and practice between medical oncolo-
gists and palliative care physicians.
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inspiration,  involvement with family and friends,  and 
by and large their quality of life [12].
Some studies have explored the causes of inadequate 
pain control and revealed the existence of both patient- 
related and physician-related barriers [13 , 14].  In terms 
of physician-related barriers,  several studies have 
assessed the obstructions to therapeutic strategies and 
shown the following barriers to exist most frequently:  
(a) inadequate assessment of pain and pain manage-
ment,  (b) patients’ reluctance to report their pain or 
give a pain score,  and (c) inadequate knowledge of pain 
management among professionals [11 , 13 , 15-18].  
However,  these studies did not take into account the 
differences in expertise among physicians.  Cancer pain 
management is typically carried out by a multidisci-
plinary team composed of various types of profession-
als,  including medical oncologists and palliative care 
physicians.  Despite this multidisciplinary approach,  it 
has not been examined whether medical oncologists 
and palliative care physicians have different attitudes 
and practices of cancer pain management.
This study aimed to evaluate whether there are dif-
ferences in the attitudes and practices of cancer pain 
management between medical oncologists and palliative 
care physicians,  using a nationwide survey in Japan.
Material and Methods
The survey questionnaire was composed of 30 ques-
tions and was constructed based on a previous report 
from the United States [18].  Most of the content was 
similar to that of this previous survey,  and was used 
with the permission of the author.  All the questions 
were close-ended.  We developed a survey website to 
collect the responses.  Completion of the survey was 
estimated to take approximately 3-4 min; this was 
stated on the website home page.  Physicians with dip-
lomate status and certification by the Subspecialty 
Board of Medical Oncology,  Japanese Society of 
Medical Oncology (JSMO) were surveyed as specialists 
in active anticancer treatment,  and those with diplo-
mate status and certification by the Specialty Board of 
Palliative Medicine,  Japanese Society of Palliative 
Medicine (JSPM).
Information about age,  gender,  years in practice,  
years in cancer treatment,  and frequency of opioid pre-
scription was required.  A 0-10 numeric rating scale 
(NRS) was used to estimate attitudes about cancer pain 
management,  with 0 indicating no agreement and 10 
indicating highest agreement with the questionnaire 
items.  The survey questions focused on the physicians’ 
ability,  knowledge about analgesics,  and education in 
cancer pain management,  and on patient barriers to 
pain treatment.
This survey was approved by the institutional review 
board of the Okayama University Hospital.  Randomized 
ID numbers for blinding and preventing double votes 
were administered and delivered by the executive office 
of the societies.  The survey for JSMO diplomates was 
performed from January to March 2013,  and the survey 
for JSPM diplomates was performed from March to 
May 2014.  Request statements with the website address 
and IDs for blinding were e-mailed to diplomates from 
the executive office of each society.  The survey data 
were downloaded from the server and analyzed.
Statistical analyses were performed with the SPSS 
statistical software package (version 16.0.1 for Windows;  
SPSS,  Chicago,  IL,  USA).  Continuous variables were 
assessed using Wilcoxon test and categorical variables 
using Fisher’s exact test.  We considered p values < 0.05 
as statistically significant.
Results
Response Rates and Sample Characteristics.
Figure 1 shows the CONSORT diagram for patient 
inclusion in this study.  A total of 1,381 physicians from 
the executive offices of JSMO and JSPM were qualified 
to participate in this study.  A total of 154 (11.1%) phy-
sicians were excluded due to missing email address 
information.  Thus,  a total of 1,227 questionnaires were 
delivered,  out of which 522 (42.5%) were returned.  Of 
these,  36 were excluded due to inconsistencies in the 
blind ID numbers,  9 due to physicians declaring dis-
agreement with the study,  and 32 because the respon-
dents were diplomates of both societies.  As a result,  
445 questionnaires were considered valid for analysis.
A total of 283 (63.6%) physicians were Diplomates,  
Subspecialty Board of Medical Oncology,  JSMO,  and 
162 (36.4%) were Diplomates,  Subspecialty Board of 
Palliative Medicine,  JSPM.  The characteristics of sur-
veyed physicians are displayed in Table 1.  The medical 
oncologists (age range: 40-49 years) were significantly 
younger than the palliative care physicians (50-59 years) 
(p < 0.001; Table 1).  In terms of gender,  29 (10.2%) of 
medical oncologists and 18 (11.1%) of palliative care 
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physicians were female,  indicating no significant differ-
ence in gender.  Similarly,  there was no significant dif-
ferences in the routine examination of cancer patients 
between medical oncologists and palliative care physi-
cians.  However,  palliative care physicians examined 
cancer patients (p = 0.004) and prescribed opioids for 
cancer pain (p = 0.008) significantly more frequently 
than medical oncologists.
Responses regarding clinical care,  attitudes and 
praetices by medical oncologists and palliative care phy-
sicians were shown in Table 2.
Attitudes. Palliative care physicians rated them-
selves as adequately relieving cancer pain (Question 1 
[Q1]: average rating: 8.0).  In contrast,  medical oncol-
ogists rated the ability of palliative care physicians to 
relieve cancer pain significantly lower (Q1: average:  
7.4).  On the other hand,  both palliative care physicians 
(Q1, 2: 4.8 < 8.0) and medical oncologists (Q1, 2:  
4.8 < 7.4) rated the ability of general physicians to relieve 
cancer pain numerically lower than their own respective 
abilities.  The rating for the accuracy of patient self- 
reports about cancer pain was not high in either group 
(Q3: medical oncologists: 5.2; palliative care physi-
cians: 5.0; p = 0.270).  In terms of potential barriers to 
optimal cancer pain management,  both medical oncol-
ogists and palliative care physicians gave “patients’ 
reluctance to take opioids due to the fear of adverse 
effects” the highest score numerically (Q4c: 5.8).  Among 
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Total: n=1,381
e-mail addresses unknown (n=154)
1,227 e-mails were sent. 
522 surveys were returned.
Inconsistencies of the blind ID numbers (n=36) 
Diplomates of both societies (n=32)
Disagreement with this study (n=9)
n=445
Medical oncologist: n=28 Palliative medicine: n=162
Fig. 1　 CONSORT diagram illustrating the enrollment of physi-
cians in the study.
Table 1　Characteristics of surveyed physicians
Medical oncologists Palliative care physicians
P value＊
n=283 % n=162 %
Age (years)
　30-39 102 36.0 8 4.9 <0.001
　40-49 134 47.3 54 33.3
　50-59 47 16.6 78 48.1
　60≤ 0 0.0 22 13.6
Gender
　Male 254 89.8 144 88.9 0.873
　Female 29 10.2 18 11.1
Routine examination of cancer patients
　Yes 271 95.8 157 96.9 0.617
　No 12 4.2 5 3.1
Frequency of daily examination of cancer patients
　Less than once a week 37 13.1 16 9.9 0.004
　About once a week 79 27.9 26 16.0
　Multiple times a week 167 59.0 120 74.1
Opportunity to prescribe opioids for cancer pain on an outpatient basis
　Less than once a week 51 18.0 31 19.1 0.008
　About once a week 75 26.5 23 14.2
　Multiple times a week 157 55.5 108 66.7
＊P values were calculated by Fisherʼs exact test.
potential barriers to optimal cancer pain management,  
palliative care physicians gave significantly higher rat-
ings to “Q4d: Physician reluctance to prescribe opioids” 
and “Q4e: Excessive regulation of opioid drugs” than 
medical oncologists.  On the other hand,  medical 
oncologists gave significantly higher ratings to “Q4f:  
Inadequate assessment of pain by physicians and medi-
cal staff ”,  “Q4g: Lack of available pain specialists or 
palliative medicine specialists”,  and “Q4h: Patient 
inability to pay for medical services or analgesics” than 
palliative care physicians.  Ratings on the other ques-
tions,  “Q4a: Patient reluctance to report pain”,  “Q4b:  
Patient reluctance to take opioids due to fear of addic-
tion”,  and “Q4c: Patient reluctance to take opioids due 
to fear of adverse effects” were not significantly different 
between the two groups.
Practice. Next,  we analyzed the responses about 
pain specialists and knowledge.  Interestingly,  there 
were significant differences in the ratings on all ques-
tions (Q5a-e) related to the reasons that general physi-
cians treating cancer patients do not refer them to pain 
specialists (i.e.,  medical oncologists and palliative care 
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Average SD Average SD
1. Are you adequately relieving cancer pain? (higher numbers signify greater adequacy)
7.4 1.2 8.0 1.4 <0.001
2. How well do general physicians relieve cancer pain? (higher numbers signify better performance)
4.8 1.6 4.8 1.4 0.472
3. How accurate do you believe patient self-reports of pain are? (higher numbers signify higher accuracy)
5.2 1.6 5.0 1.6 0.270
4. Rate the significance of the following potential barriers to optimal cancer pain management (higher numbers indicate greater barriers)
　　a. Patient reluctance to report pain 4.5 2.3 4.6 2.4 0.677
　　b. Patient reluctance to take opioids due to fear of addiction 5.1 2.5 5.1 2.5 0.750
　　c. Patient reluctance to take opioids due to fear of adverse effects 5.8 2.3 5.8 2.2 0.844
　　d. Physician reluctance to prescribe opioids 2.7 2.5 4.1 2.5 <0.0001
　　e. Excessive regulation of opioid drugs 3.2 2.7 5.6 2.7 <0.0001
　　 f. Inadequate assessment of pain by physicians and medical staff 5.4 2.3 3.3 2.6 <0.0001
　　g. Lack of available pain specialists or palliative medicine specialists 5.0 2.8 3.8 2.5 <0.0001
　　h. Patient inability to pay for medical services or analgesics 3.5 2.0 2.9 2.2 <0.001
5.  Rate the reasons why general physicians treating cancer patients do not refer them to pain specialists (higher numbers indicate greater 
significance)
　　a. Pain specialists are not available in my region 6.5 2.7 3.7 2.6 <0.001
　　b. Pain specialists do not want to treat cancer patients 3.4 2.5 3.9 2.4 0.016
　　c. Appointments with pain specialists are difficult to get 4.5 2.9 6.6 2.0 <0.001
　　d. Pain specialists tend to immediately perform invasive treatment 2.7 2.1 5.1 2.3 <0.001
　　e. Pain specialists do not understand oncology 3.4 2.6 3.8 2.2 0.023
6. Rate the following (higher numbers signify more agreement)
　　a.  Opioids are the first-line approach for moderate to severe chronic pain 
associated with cancer
8.3 2.3 8.1 2.3 0.247
　　b.  Regularly scheduled opioid dosing is more effective than as-needed 
dosing for chronic cancer pain
9.0 1.4 8.8 1.7 0.230
　　c.  Opioids are less effective for neuropathic pain than non-steroidal 
anti-inflammatory drugs and/or antiepileptic agents
5.3 2.6 4.5 2.7 0.001
7. Rate the following (higher numbers signify greater adequacy)
　　a.  The adequacy of education and training about cancer pain manage-
ment in medical school in Japan
3.5 2.1 3.3 2.0 0.441
　　b.  The adequacy of education and training about cancer pain manage-
ment in residency in Japan
3.8 2.1 3.6 1.9 0.711
＊P values were calculated by Wilcoxon test,  SD,  standard deviation.
physicians).  Medical oncologists gave significantly 
higher ratings on “Q5a: Pain specialists are not avail-
able in my region” than palliative care physicians.  On 
the other hand,  palliative care physicians gave signifi-
cantly higher ratings on “Q5b: Pain specialists do not 
want to treat cancer patients”,  “Q5c: Appointments 
with pain specialists are difficult to get”,  “Q5d: Pain 
specialists tend to immediately perform invasive treat-
ment”,  and “Q5e: Pain specialists do not understand 
oncology” than medical oncologists.
With regard to questions about commonly accepted 
clinical practices for pain relief,  the surveyed physicians 
in both groups gave high ratings on two out of the three 
questions:  “Q6a: Opioids are the first-line approach 
for moderate to severe chronic pain associated with 
cancer (medical oncologists: 8.3; palliative care physi-
cians: 8.1)” and “Q6b: Regularly scheduled opioid 
dosing is more effective than as-needed dosing for 
chronic cancer pain (medical oncologists: 9.0; pallia-
tive care physicians: 8.8)”.  However,  ratings on “Q6c:  
Opioids are less effective for neuropathic pain than 
non-steroidal anti-inflammatory drugs and/or antiepi-
leptic agents” were lower.
Training. Regarding the questions on education,  
Q7a and b: The adequacy of education and training 
about cancer pain management in medical school and in 
residency in Japan,  there were no significant differences 
between the ratings of medical oncologists and pallia-
tive care physicians,  although both groups gave rela-
tively low ratings for both education and training in 
medical school and residency (range: 3.3-3.8).
Discussion
Our results indicate that medical oncologists and 
palliative care physicians have different attitudes and 
practices of cancer pain management.  Five of the eight 
questions (Q4a-h about the potential barriers to optimal 
cancer pain management were rated significantly differ-
ently by medical oncologists and palliative care physi-
cians.  Furthermore,  the ratings on all five questions 
about pain specialists (Q5a-e) were significantly differ-
ent between the 2 groups.  We also found that both 
medical oncologists and palliative care physicians con-
sidered “patient reluctant to take opioids due to fear of 
adverse effects” as the most important barrier to opti-
mal cancer pain management,  and they believed that 
more intensive education and training on cancer pain 
management were needed in medical school and resi-
dency.
The several previous studies conducted to assess 
cancer pain management did not take into consider-
ation the differences in physicians’ majors.  With regard 
to physician-related barriers,  in a survey conducted by 
the Eastern Cooperative Oncology Group (ECOG) in 
1993,  76% of physicians rated poor pain assessment as 
an important barrier to adequate pain management 
[11].  Other barriers reported were: patient reluctance 
to report pain (62%),  patient reluctance to take analge-
sics (62%),  and physician reluctance to prescribe opi-
oids (61%) [11].  According to the results of the present 
study,  these barriers remain unresolved over 30 years 
later.  In our survey in Japan,  patient reluctance to take 
opioids due to fear of adverse effects was one of the 
most important barriers as rated by both medical 
oncologists and palliative care physicians.  Interestingly,  
of these four previously reported barriers,  2 had sig-
nificantly different ratings between medical oncologists 
and palliative care physicians in our findings.  One of the 
countermeasures to overcome these barriers may be to 
develop effective education for physicians.  Our survey 
also revealed poor ratings with respect to education and 
training in cancer pain management in medical school 
and during residency by both medical oncologists and 
palliative care physicians.  Many physicians feel they do 
not have sufficient opportunities to learn about cancer 
pain management.  In 2007,  the Cancer Control Act 
was approved in Japan.  Initiated by the Japanese gov-
ernment,  this plan promotes a cancer-control program 
that includes basic palliative care training for physicians 
who participate in the treatment of patients with cancer.  
This program is managed by JSPM and is called the 
Palliative care Emphasis program on symptom manage-
ment and Assessment for Continuous medical Educa-
tion (PEACE) project,  and is expected to deal with 
physician barriers with respect to knowledge of opioids 
[19].  Although medical schools in Japan have recently 
added some palliative medicine curriculum,  in most 
cases this consists of only about 2 h of lecture time over 
6 years of medical education,  and there is not system-
atic curriculum developed specifically for clinical physi-
cians.  An evaluation of and reflection on these topics is 
needed.  Moreover,  physicians may require education in 
areas of specialization outside of their fields — e.g.,  
medical oncologists may benefit from education in pal-
liative care,  and palliative care physicians from educa-
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tion in oncology.
Because cancer pain originates from a complex set of 
causes,  cancer pain management should be conducted 
by multidisciplinary teams including various specialty 
physicians and nurses,  pharmacists,  nutritionists,  
physiotherapists,  and so on.  This multidisciplinary 
approach aims to alleviate distress by controlling symp-
toms,  including cancer pain,  as well as by attention to 
psychosocial concerns.  Team members also seek to 
facilitate care and advance communication between 
professionals and the individual patient and family.  A 
meta-analysis of 19 studies to assess the effectiveness of 
palliative and hospice care multidisciplinary teams 
demonstrated that these teams have benefits for allevi-
ating patients’ pain and other symptoms [20].  To max-
imize the effectiveness of treatment,  it may be necessary 
for professionals to recognize each other’s differences 
and strengths when deciding on a treatment strategy.  
Our findings showed that both groups of physicians 
surveyed,  but especially the palliative care physicians,  
thought they had adequate ability to relieve cancer pain 
in their patients (Q1),  but rated the ability of general 
physicians to relieve cancer pain as lower than their 
own (Q2).  As there were no patient-reported outcomes 
assessed in our survey,  we did not have data regarding 
which experts actually show the best performance on 
cancer pain management.
Another issue reported was inaccessibility to pain 
specialists.  One of the reasons for this inaccessibility 
may be a shortage in the number of pain specialists in 
Japan,  because anesthesiologists are permitted to per-
form cancer pain control along with practicing general 
anesthesia.  Interestingly,  there were significant differ-
ences in the ratings on all the questions related to the 
question of why general physicians do not refer their 
cancer patients to pain specialists (Q5a-e).  Palliative 
care physicians gave significantly higher ratings than 
medical oncologists on four of these 5 questions.  These 
differences may have been due to the different frequen-
cies of daily examination of cancer patients and differ-
ent opportunities to prescribe opioids between the 
practice of the 2 types of specialists.
There were several limitations in this study.  First,  
the response rate,  which was only 40% despite reminder 
emails,  may not be sufficient,  although the average 
response rate of previous Internet surveys was 34% 
(min. 7%-max. 89%) [21].  Second,  our survey was 
conducted only with physicians,  and did not include 
patients.  There may be unknown gaps between physi-
cians and patients that could lead to false-negative or 
-positive results.  Third,  there may be a multiplicity of 
issues caused by the use of multiple statistical tests,  and 
they may lead to false-positive results.
In spite of these limitations,  overall our observa-
tions were consistent with the previously reported bar-
riers and the hypothesis that medical oncologists and 
palliative care physicians have different attitudes and 
practices of cancer pain management.  To our knowl-
edge,  this is the first study to assess the attitudes and 
practices of cancer pain management by medical oncol-
ogists and palliative care physicians separately.  Several 
similar physician surveys have been performed in other 
countries without any stratification by physician spe-
cialties [15 , 19 , 22-25].  In the present survey,  we 
selected medical oncologists and palliative care physi-
cians as opioid prescribers,  because they are authorized 
by certification examinations administered by medical 
societies,  and therefore represent a restricted popula-
tion.  For effective cancer pain management,  it is 
important to account for differences in the attitudes and 
practices between medical oncologists and palliative 
care physicians.
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